Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Russia’s Potential COVID-19 Vaccine Proven Safe and Well-Tolerated in First Clinical Trial

By HospiMedica International staff writers
Posted on 17 Jul 2020
Russia has claimed to have developed a safe vaccine against the novel coronavirus, following the completion of clinical trials of a potential COVID-19 vaccine candidate that was developed locally.

The Sechenov University (Moscow, Russia) has finished a clinical study of the COVID-19 vaccine developed by the Gamalei Institute of Epidemiology and Microbiology (Moscow, Russia). More...
This is the first and only Russian-made vaccine against COVID-19 shortlisted by the World Health Organization in their report on 23 clinical trials around the world.

For the trials, the Sechenov University recruited 38 healthy volunteers, out of which the first group of 18 people received the vaccine on June 18 and the second group of 20 people on June 23. The tested vaccine has been proved safe for the patients, which was the key result of the clinical study, according to Yelena Smolyarchuk, Head of the Sechenov University Centre for Expert Evaluation of Medicinal Products.

Additionally, the Russian Defense Ministry has reported that the vital signs of the volunteers remained within normal limits for 28 days after vaccination. All the volunteers have been discharged from hospital but will remain under observation for the next six months to see if they develop any health issues due to the vaccine over the long-term. Before being discharged from the hospital, the volunteers were made to undergo a medical check-up and pass a blood test to find out if they had developed an immune response to the SARS-CoV-2 virus.

In a video released by the Defense Ministry, researcher Svetlana Volchikhina said, “Their immunity is working well, antibodies are being created, they are protected against the coronavirus.” The results of the trials ‘allow us to speak with confidence about the safety and good tolerability of the vaccine,’ the Defense Ministry said in a statement.

Related Links:
Sechenov University
Gamalei Institute of Epidemiology and Microbiology



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.